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Previous studies of CTL responses to influenza peptides in HLA single transgenic mice resulted in the identification of
at most one immunodominant epitope. Since HLA-B*3501 is known to present multiple HIV-1-specific T cell epitopes we
tested the cellular immune response of HLA-B*3501 transgenic mice to synthetic HTLV-1 peptides mixed with the lipohexa-
peptide N-palmitoyl-S-[2,3-bis(palmitoyloxy)propyl]cysteinyl-seryl-lysyl-lysyl-lysyl-lysine, which is a biocompatible, Th-epitope-
independent adjuvant. Eleven of 37 tested HLA-B*3501 binding peptides mounted a CTL response after three in vitro
stimulations. The HLA-B*3501 affinity of peptides correlated with their ability to induce CTL in HLA-B*3501 transgenic mice.
Seven peptides derived from env-gp46 (VPSPSSTPLL, VPSSSSTPL, YPSLALAPH, and YPSLALAPA), pol (QAFPQCTIL), gag-
p19 (YPGRVNEIL), and tax (GAFLTNVPY) proteins induced peptide-specific CTL. Bulk CTL generated by four peptides
derived from env-gp46 (SPPSTPLLY, VPSPSSTPLLY, and VPSPSSTPLL) and pol (QAFPQCTILQY) killed peptide-pulsed and
recombinant vaccinia-infected target cells. The latter peptides therefore present T-cell epitopes and are vaccine candidates
for our transgenic mouse model. q 1996 Academic Press, Inc.
INTRODUCTION adult T-cell leukemia. Symptomatic treatment of HAM with
cortisone derivatives and a-interferon yields only tempo-
Human T-cell leukemia virus type-1 is a member of rary beneficial effects. Therefore a vaccine is needed in
the subfamily Lentiviriae and of the family Retroviridae. order to prevent HTLV-1 infection and the onset of the
The virus occurs endemically in Southwest Japan, the disease. Two approaches were taken to develop a HTLV-1
Caribbean islands, Melanesia, and Central Africa. About vaccine. Lairmore and co-workers (1992) defined antigenic
1.2 million Japanese are infected with HTLV-1. More than epitopes that elicited an antibody response. The second
half of them live on the islands of Kyushu, Shikoku, and approach is based on the observation that CTL play an
Kinki (Mueller, 1991; Blattner, 1990). Depending on host important role in the viral clearance of an infected host
factors, such as HLA haplotype (Sonoda et al., 1996), and the acquisition of protective immunity. Since the dis-
HTLV-1 infection may lead after a long asymptomatic covery of the HTLV virus in 1980 (Poiesz et al., 1980),
course either to HAM (HTLV-1 associated myelopathy)/ several groups attempted the identification of HTLV-1 T
TSP (tropical spastic paraparesis) (Gessain et al., 1985; cell epitopes and the elucidation of CTL’s role in the course
Osame et al., 1986) or to adult T-cell leukemia (Uchiyama of various HTLV-1-associated diseases. Most of the HTLV-
et al., 1977; Yoshida et al. 1984). 1 T-cell epitopes derived from human T cell clones were
There is no effective treatment for either HAM/TSP or mapped to the tax protein (Parker et al., 1994; Daenke et
al., 1996), perhaps because tax is persistently expressed
in infected individuals.
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particular the transfer of this method to a transgenic mouse B*3501 peptide motif using FINDPATTERNS (GCG pack-
age 7.3.1; Wisconsin Computer Group, Madison, WI).model enables the identification of HLA class-I-restricted
peptide epitopes that induce specific CTL. Sixty-four 8-mer to 12-mer peptides that matched the
HLA-B*3501 query sequence motif were synthesized inStudies of HLA-restricted CTL in HLA-A2, Cw3
transgenic mice, and HLA-B27/hb2m double transgenic a multiple peptide synthesizer (Shimadzu Model PSSM-
8) using F-moc chemistry (Nokihara et al., 1992). In addi-mice were based on immunization with influenza or Sen-
dai virus. Induction of HLA-A2-restricted influenza virus- tion one peptide (YSPNVSVPS) was synthesized as a
nonbinding control since its anchor residues do not cor-specific CTL was mostly unsuccessful. However, pep-
tides derived from influenza or Sendai viruses induced respond to the HLA-B*3501 motif. Three peptides (YSP-
LALAPH, YPSLALAPA, and YPSLALAGA) that match theHLA-B27- or Cw3-restricted CTL (Kievits et al., 1987; Dill
et al., 1988). The construction of transgenic mice ex- N-terminal anchor residue Pro, but show conservative
changes (Tyr r His; Leu/Ile/Met r Ala) at the C-terminuspressing a chimeric class I molecule (Vitiello et al., 1991)
provided the basis for the successful identification of were chosen for synthesis to investigate the effect of
substitutions by amino acids with similar chemical prop-multiple epitopes inducing HPV-16 (Ressing et al., 1995)-
or HCV (Shirai et al., 1995)-specific HLA-A*0201-re- erties.
stricted CTL. These chimeric mice express the a1/a2
Peptide binding assaydomain of HLA-A*0201 and the a3 domain of H2-Kb.
Therefore the CD8/ T cells can interact with the synge- HLA-B*3501 peptide binding was tested essentially as
neic a3 domain (Sekimata et al., 1993; Kalinke et al., described previously (Takamiya et al., 1994; Scho¨nbach
1993) of the hybrid HLA molecule. Despite the advantage et al., 1995). Briefly, RMA-S cells (Ljunggren et al., 1985,
of the chimeric HLA transgenic murine lines we decided 1990) expressing H-2b but lacking a functional TAP-2
to use transgenic mice expressing the a1 to a3 domain were transfected with the HLA-B*3501 gene. RMA-S-
of HLA-B*3501 in order to assess the effect of peptide- B*3501 cells, cultured for 14 hr at 267, were pulsed with
HLA affinity in context of weak CD8-HLA-B*3501 interac- peptides at concentrations of 5 1 1004 –5 1 1009 M,
tions on the immunogenicity of HLA-binding peptides. incubated for 3 hr at 377, and stained with anti-HLA-Bw6
Effective immunization with peptides requires powerful monoclonal antibody SFR8-B6 (Radka et al., 1982) and
adjuvants. However, strong adjuvanticity, for example, of the fluorescein-conjugated IgG fragment of sheep anti-
complete Freund’s adjuvant or the synthetic lipopenta- mouse immunoglobulin (Silenius Laboratories, Haw-
peptide P3C-Ser-Ser-Asn-Ala of bacterial lipoprotein, is thorn, Victoria, Australia). The mean fluorescence inten-
often overcast by undesired pyrogenic and toxic side sity was measured with a FACScan flow cytometer (Bec-
effects (Reitermann et al., 1989). In search for an ton–Dickinson Co., Mountain View, CA). Peptides were
adjuvant without harmful side effects we have selected classified as nonbinders if they yielded less than 25% of
the synthetic lipohexapeptide N-palmitoyl-S-[2,3-bis- the background-corrected mean fluorescence intensity
(palmitoyloxy)propyl]cysteinyl - seryl - lysyl - lysyl - lysyl - of RMA-S-B*3501 cells. Binding peptides were further
lysine [P3C-Ser-(Lys)4]. The immunological active grouped according to their binding indices (BI) into low
principle of P3C-Ser-(Lys)4 is the synthetic N-terminal tri- (0.01  BI ⁄ 0.001), medium (0.1  BI ⁄ 0.01), and high
palmitoyl-S-glycerylcysteine, which occurs as murein (BI ⁄ 0.1) binders. BI corresponds to the half-maximal
component in the outer membrane of Escherichia coli binding value (BL50) of HLA-B*3501 self-peptide 37F (LPF-
and other gram-negative enterobacteria (Hantke et al., DFTPGY) divided by the BL50 value of the tested peptide.
1973). Previous studies on the water soluble, amphiphilic
P3C-Ser-(Lys)4 that triggers lysozyme release from neu- HLA-B*3501 transgenic mice
trophils have demonstrated immunoadjuvant function in
C3H/He mice expressing HLA-B*3501 at high levelsantigen-specific IgM and IgG antibody production (Reit-
were produced by injecting a 6.4-kb EcoRI fragment car-ermann et al., 1989) as well as in in vivo priming of murine
rying the HLA-B*3501 gene into one-cell embryos as de-CTL (Deres et al., 1989). Peptide–P3C-Ser-(Lys)4 mixtures
scribed by Karaki and co-workers (1993). Surviving em-are of great practical interest as an easily producible,
bryos were reimplanted into the oviducts of pseudopreg-biocompatible, and apparently Th cell epitope-indepen-
nant ICR female mice. Integration of the transgene indent vaccine (Borges et al., 1994). Here we used P3C-Ser-
offspring mice was tested by dot-blot hybridization of(Lys)4 mixed with HTLV-1-derived, HLA-B*3501 binding
tail DNA with a HLA-B*3501-specific probe. The 340-bppeptides to induce virus and peptide-specific HLA-
probe containing exons 6 and 7 of the HLA-B*3501 geneB*3501-restricted CTL in transgenic mice.




Approximately 1 1 105 peripheral blood lymphocytes
or splenocytes suspended in 50 ml of phosphate-bufferedHTLV sequences were searched for sequence pat-
terns [x-(P,A)-x3-x7-11(Y,L,I,M)] which resemble the HLA- saline (PBS) were incubated with 50 ml of diluted FITC-
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ature with a peroxidase-conjugated goat affinity-purified
F(ab*)2 fragment of mouse immunoglobulins (CAPPEL,
West Chester, PA). Following another three washes the
HLA-B*3501 antigen was detected by an enzyme assay
(HRP KIT IS-50B; Konica, Japan).
Immunization of HLA-B*3501 transgenic mice
Eight- to ten-week-old transgenic mice of both sexes
were used throughout the experiments. At least two mice
were immunized with each peptide. HLA-B*3501-binding
peptide at 100 mM and 100 mg P3C-Ser-(Lys)4 in 400 ml
PBS (for one mouse) was sonicated for 15 min in an
ultrasonic bath. The mixture was intraperitoneally in-
jected. Seven to ten days after the immunization, spleens
and cervical and inguinal lymph nodes were aseptically
removed.
In vitro stimulations
FIG. 1. Schematic structure of HTLV-1. Boxes present HTLV-1 pro-
Lymphocytes were cultured at 2 1 106 cells/ml in com-teins. The number of amino acid residues is shown below or above
each box. Arrows indicate WR recombinants. plete medium containing 100 U/ml human recombinant
IL-2, 10% supernatant of concavalin-A-induced rat spleen
cells, and 50 mM 2-mercaptoethanol. Bulk cultures (2 1
conjugated W6/32 anti-HLA class I monoclonal antibody 106 cells) were maintained by weekly stimulation with
(Barnstable et al., 1978; Kahn Perles et al., 1987) for 30 concavalin-A-induced, g-irradiated (35 Gy) autologous
min on ice. Following three washes with PBS mean fluo- spleen cells (1 1 106/ml) pulsed with 10 mM peptide.
rescence intensity was measured by a FACStar.
Recombinant vaccinia virus
Western blot analysis
Recombinant vaccinia viruses which express HTLV-1
proteins (Fig. 1) WR-proenv, WR-gag, WR-p40x (tax), WR-Tissue extracts were resolved on a 12% SDS–poly-
p27x (rex), WR-p21x, WR-polA, WR-polB, and WR-polCacrylamide gel and transferred to a polyvinylidene difluor-
recombinant vaccinia and a control recombinant vac-ide transfer membrane using a Bio-Rad apparatus (Rich-
cinia, WR-HA, were constructed as previously describedmond, CA). For immunostaining, the membrane was incu-
by Shida (1987) or Parker and co-workers (1994).bated with gentle agitation for 1 hr at room temperature
with anti-HLA class I a3 domain mAb, TP25.99 (D’Urso
Cytotoxic T lymphocyte assayet al., 1991; Tanabe et al., 1992). The membrane was
then washed three times by soaking for 10 min each P815 and P815-B*3501 (Livingston et al., 1995)
transfectants were infected with 5 plaque-forming units/wash in TBS (pH 7.2), and stained for 1 hr at room temper-
FIG. 2. Expression of HLA-B*3501 molecules in HLA-B*3501 transgenic mice. (A) Surface expression of HLA-B*3501 molecules on the surface
of splenocytes and PBL of HLA-B*3501 transgenic mice. Both cells were stained with FITC-labeled W6/32 mAb (solid line) and without FITC-labeled
W6/32 mAb (dotted line) and analyzed by flow cytometry. FITC-labeled W6/32 mAb did not bind to PBL and splenocytes from C3H/He mice. (B)
Expression of HLA-B*3501 molecules in multiple tissues of HLA-B*3501 transgenic mice. Extracts from various tissues of HLA-B*3501 transgenic
mice (odd numbers) and C3H/He mice (even numbers) were transferred to a membrane. The Western blot was stained with TP25.99 mAb and
peroxidase-conjugated goat anti-mouse immunoglobulin. L cells expressing HLA-B*3501 (Karaki et al., 1993) were used as positive control.
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TABLE 1
HLA-B*3501 Binding Peptides Used to Immunize HLA-B*3501 Transgenic Mice
CTL recognition
Peptides HTLV-1 strains Protein Position BI Peptide Virus
8-mers
DALSAQLY RH/K34, -K30 rex 80–87 0.719a 0 NT
PAYIVPTY RH/K34, -K30 rex 57–64 0.082 0 NT
EAGHIEPY ATK, HS35 pol 49–56 0.004 0 NT
9-mers
YPSLALAPH A  G, 265 env-gp46 257–265 1.254 / 0
VPSSSSTPL ATK, MT-2 env-gp46 247–255 0.958 / NT
SPSSTPLLY HS35 env-gp46 249–257 0.784 0 0
SPPSTPLLY 1010/3 env-gp46 249–257 0.784 / /
QAFPQCTIL ATK, HS35 pol 177–185 0.627 / /
SAVLLLDKY ATK, HS35 pol 376–384 0.153 0 0
TPLKNTSVL ATK, HS35 vprt 81–89 0.128 0 0
RPAYIVTPY RH/K34, -K30 rex 56–64 0.062 0 0
GAFLTNVPY ATK, HS35 tax 185–193 0.058 / 0
YPSLALAGA P  G, 264 env-gp46 257–265 0.058 0 0
YPSLALAPA ATK, MT-2 env-gp46 257–265 0.058 / 0
LPMDNALSI ATK, HS35 pol 777–785 0.046 0 0
YPGRVNEIL ATK, MT-2, HS35 gag-p19 76–84 0.029 / 0
DPILRSLAY ATK, MT-2, HS35 gag-p24 296–304 0.026 0 0
IAHLGKPSY ATK pol 709–717 0.005 0 0
WVSKGTPTL ATK, HS35 pol 271–279 0.003 0 0
10-mers
CPNLVSYSSY ATK, MT-2 env-gp46 67–76 0.460 0 0
IPLPKQFQPY ATK, HS35 pol 122–131 0.197 0 0
TPLLYPSLAL ATK, HS35 env-gp46 253–262 0.012 0 0
VPSPSSTPLL HS35 env-gp46 247–256 0.004 / 0
11-mers
CPYTGAVSSPY ATK, HS35 env-gp46 122–132 4.059 0 0
VPSSSSSPLLY HTVEGP4B_1 env-gp46 247–258 4.059 0 NT
QAFPQCTILQY ATK, HS35 pol 177–187 1.500 / /
VPSSSSTPLLY ATK, MT-2 env-gp46 247–257 0.493 0 0
FAFTVPQQCNY ATK, HS35 pol 132–142 0.197 0 0
VPSPPSTPLLY 1010/3 env-gp46 247–257 0.090 / 0
VPSPSSTPLLY HS35 env-gp46 247–257 0.050 / /
LPRLLSRKVVY ATK, HS35 pol 559–569 0.056 0 0
LAIRHTTHVPY ATK, HS35 pol 738–748 0.023 0 0
CPINYSLLASL ATK, MT-2, HS35 gag-p19 61–71 0.020 0 0
SVPSSSSTPLL ATK, MT-2 env-gp46 246–256 0.008 0 NT
VPYKRIEELLY ATK, HS35 tax 191–201 0.002 0 0
12-mers
FPFSLLVDAPGY ATK, MT-2 env-gp46 159–170 0.161 0 0
TPKDPILRSLAY ATK, MT-2, HS35 gag-p24 293–304 0.011 0 0
Controls
LPFDFTPGY HLA-B*3501 self 0.690 NT NT
peptide
YSPNVSVPS ATK, MT-2 env-gp46 241–249 0.001 0 0
a BI ⁄ 0.1, high binders; 0.1  BI ⁄ 0.01, medium binders; 0.01  BI ⁄ 0.001, low binders. NT, not tested.
cell of recombinant vaccinia virus expressing HTLV-1 peptide at 377 for 1 hr. One hundred microliters of effector
cells was added to 100 ml of target cells and incubatedproteins or control recombinant vaccinia, WR-HA, for 12 –
14 hr before labeling 1 1 106 cells with 100 mCi 51Na2- for 4 hr.
CrO4 in 100 ml at 377 for 1 hr. RMA-S and RMA-S-B*3501
(P815 and P815-B*3501) cells cultured at 267 (377) were RESULTS
incubated at 5 1 106 cells with 100 mCi 51Na2CrO4 in 100 Generation of HLA-B*3501 transgenic mice
ml at 267 (377) for 1 hr. Following three washes, cells
were diluted to 5 1 104 cells/ml. RMA-S and RMA-S- HLA-B*3501 transgenic mice were produced by in-
jecting the 6.4-kb EcoRI fragment of the HLA-B*3501B*3501 cells were labeled with 1 1 1005 to 1 1 1008 M
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FIG. 3. HLA-B*3501 binding of CTL-inducing HTLV-1 peptides. RMA-S-B*3501 cells cultured for 14 hr at 267 were loaded with peptides at
concentrations of 5 1 1004 – 5 1 1009 M and incubated for 3 hr at 377. Peptide-loaded cells were subsequently labeled with anti-HLA-Bw6 mAb
SFR8-B6 and FITC of sheep anti-mouse IgG. The mean fluorescence intensity was measured with FACScan flow cytometer. The peptides YPSLALAPH,
VPSSSSTPL, SPPSTPLLY, QAFPQCTIL, and QAFPQCTILQY were evaluated as high binders. Peptide VPSPSSTPLL is a low binder, while the
remaining peptides are medium binders.
gene into C3H/He (H-2k) one-cell embryos. Offspring residues at position 2. However, previous peptide bind-
mice that tested positive for the presence of the 340-bp ing studies (Takamiya et al., 1994) showed that the 12-
BglII–XbaI exon 6 and 7 fragment were further analyzed mer peptide LPFDFTPGGGGY bound efficiently to HLA-
for the surface expression of HLA-B*3501 molecules on B*3501 molecules and that C-terminal anchor residues
peripheral blood lymphocyte and spleen cells by flow (Tyr, Phe, Leu, Ile, and Met) found in 9-mers functioned
cytometry with FITC-conjugated anti-HLA class I mAb equally as anchor residues in 10-mers and 11-mers
W6/32 (Fig. 2A). The latter binds to all HLA class I mole- (Scho¨nbach et al., 1995).
cules (Barnstable et al., 1978), but not to H-2k molecules The binding of 68 8- to 12-mer HTLV-1 peptides was
(Kahn-Perles et al., 1987). The results shown in Fig. 2A tested at concentrations of 5 1 1004 –5 1 1009 M and
therefore indicate that PBL and spleen cells of the binding affinities of peptides carrying Pro or Ala at posi-
transgenic mice express HLA-B*3501 molecules. The ex- tion 2 and Tyr, Leu, Ile, Ala, or His at the C-terminus were
pression of HLA-B*3501 molecules was almost identical compared to that of HLA-B*3501 binding self-peptide 37F
to that of H-2k molecules in the transgenic mice. The (LPFDFTPGY). Thirty-one peptides did not bind to HLA-
mean fluorescence intensities of PBL stained with FITC- B*3501 (BI  0.001). Thirty-seven peptides (55.1%) were
labeled W6/32 mAb and FITC-labeled anti-H-2Kk mAb evaluated as HLA-B*3501 binding peptides (Table 1). Six-
were 63.3 and 62.2, respectively. teen peptides belonged to high binders (BI ⁄ 0.1), 15 to
Multiple tissue Western blotting revealed high expres- medium binders (0.1  BI ⁄ 0.01), and 6 to low binders
sion of HLA-B*3501 molecules in lung, spleen, thymus, (0.01  BI ⁄ 0.001). Among the 16 high binders were 1
and skin. Heart and brain expressed HLA-B*3501 at low 8-mer, 7 9-mer, 2 10-mer, 5 11-mer, and 1 12-mer pep-
to medium levels (Fig. 2B). HLA-B*3501 molecules are tides. The results confirmed our previous findings which
expressed in most tissues of HLA-B*3501 transgenic showed that peptides longer than 9-mers bound effi-
mice, indicating that the expression of HLA-B*3501 mole- ciently to HLA-B*3501 molecules.
cules in transgenic mice resembles that of endogenous One high binder (YPSLALAPH) and two medium
H-2 class I molecules. binders (YPSLALAGA and YPSALAPA) carried His or
Ala at the C-terminus. The latter residues were not
HLA-B*3501 binding of HTLV-1 peptides
found in the HLA-B*3501 peptide motif determined by
pool sequencing. However, the binding of syntheticPooled sequence data of HLA-B*3501-eluted self-pep-
peptides carrying the aromatic residue His and ali-tides (Falk et al., 1993, 1994) revealed the aromatic resi-
phatic residue Ala indicated that their structural anddues Tyr and Phe and aliphatic hydrophobic residues
chemical properties are sufficient to allow HLA-B*3501(Leu, Ile, and Met) as main anchor residues in 9-mers
while Pro and Ala were specified as auxiliary anchor F-pocket interactions.
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FIG. 4. Peptide-specific bulk CTL. Killing of RMA-S-B*3501 cells loaded with 1006 M peptide. Bulk T cells were stimulated three times with
peptides, except bulk CTL induced with peptide QAFPQCTIL. The latter required four in vitro stimulations. Nonbinder YSPNVSVPS (Table 1) which
does not elicit specific CTL was used as negative control. The effector target ratio was 40:1 (A) or 40, 20, and 10:1 (B).
Induction of peptide-specific CTL in HLA-B*3501 one of the immunized HLA-B*3501 transgenic mice a
peptide- or virus-specific CTL response. Another six pep-transgenic mice
tides (env SPPSTPLLY, VPSPSSTPLL, VPSSSSTPL, VPS-
Thirty-seven HLA-B*3501 binding peptides were exam- PPSTPLLY, YPSLALAPA, and pol QAFPQCTIL) which
ined upon in vivo CTL induction in HLA-B*3501 present variants or mutants of peptides deduced from
transgenic mice. Seven to ten days after ip injection of different HTLV-1 isolates—showing a homology of 78–
the peptide–P3C-Ser-(Lys)4 mixture lymph nodes and 89%—generated a CTL response, too. Considering
spleen were dissected. After the second or third in vitro these homologous peptides, altogether 11 (Figs. 3 and
stimulation of the lymph node- and spleen cell-derived 4A) of 37 peptides mounted a CTL response.
bulk cultures, the peptide-specific CTL activity was as- Specific CTL activity was not observed after two in
sessed by using RMA-S-B*3501 cells loaded with the vitro stimulations of bulk cultures derived from peptide-
corresponding peptide. immunized transgenic mice. Three in vitro stimulations
Five nonhomologous peptides (gag YPGRVNEIL, pol were sufficient to elicit a killing activity of 15–40% among
QAFPQCTILQY, env VPSPSSTPLLY, YPSLALAPH, and tax 11 peptide-stimulated bulk cultures. The CTL showed
HLA-B*3501 restriction since RMA-S cells (H-2b) loadedGAFLTNVPY) of 37 peptides (Table 1) induced in at least
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FIG. 5. Virus-specific CTL. Cytotoxic activity of bulk CTL after three in vitro stimulations with peptides. P815 and P815-B*3501 target cells were
infected with 5 PFU recombinant virus. The effector:target ratio was 40:1.
with peptide were lysed at background level. Moreover, sponding epitopes presented on P-815-B*3501 cells in-
specific CTL were not detected in peptide- or adjuvant- fected with recombinant vaccinia virus. Four (env SPP-
stimulated bulk cultures of adjuvant-immunized HLA- STPLLY, VPSPSSTPLL, and VPSPSSTPLLY and pol QAF-
B*3501 transgenic mice (data not shown). No specific PQCTILQY) of 11 peptides generated CTL that killed
CTL response was observed against nonbinder YSP- target cells infected with pro-env or polB recombinant.
NVSPS (Fig. 4A). Therefore in our immunization protocol, The latter results suggest that the four peptides resemble
peptide-specific CTL are not induced without prior in vivo naturally processed HTLV-1 epitopes (Fig. 5). Since a
immunization and multiple in vitro stimulation with the recombinant of the Caribbean strain encoding env VPS-
corresponding peptide. PSSTPLLY was not available and target cells loaded with
Five env peptides (VPSPSSTPLLY, VPSPSSTPLL, VPS- peptides resembling both strains were equally lysed, we
SSSTPL, SPPSTPLLY, and VSPPSTPLLY) derived from infected the target cells with an env recombinant derived
the Japanese [ATK, MT-2 (Seiki et al., 1983; Gray et al., from the Japanese HTLV-1 strain ATK which carries the
1990)] and Caribbean [HS35 and 1030/3 (Malik et al., env sequence VPSSSSTPLLY.
1988)] HTLV-1 strains generated CTL responses of 18– CTL induced by peptides SPPSTPLLY, VPSPSSTPLLY,
25% at E:T ratios of 40:1 (Fig. 4A). Despite the amino and VPSPSSTPLL which differ from the recombinant
acid substitutions VPSP(S r P)(S r P)SSTPLLY the env (VPSSSSTPLLY) at position 3 and/or 4 killed target cells
region of both Caribbean and Japanese strains appears at a level of 30–20%. The lower cytotoxicity of 10-mer
to be conserved in terms of immunogenicity. CTL induced peptide VPSPSSTPLL is attributed to the low HLA-B*3501
by peptides gag YPGRVNEIL and tax GAFLTNVPY lysed affinity (Figs. 3 and 4A). Hence the single substitution of
RMAS-B*3501 cells loaded with the respective peptides Ser r Pro at position 4 does not affect the cytotoxicity.
at levels of 60–70% and RMAS-B*3501 without peptide at On the other hand the double substitution Ser r Pro at
levels of 35 and 40%. The high background was probably positions 2 and 3 of 9-mer SPPSTPLLY reduced the killing
caused by NK-mediated killing (Raulet et al., 1995). activity nearly two times at the E:T ratio of 40:1 compared
CTL induced by 9-mer peptide QAFPQCTIL required to the epitope VPSPSSTPLLY (Fig. 5). This result sug-
four in vitro stimulations to mount a CTL response of 22% gests that the third of the four Ser residues is involved
specific lysis (Fig. 4A), whereas peptide QAFPQCTILQY in T cell receptor recognition.
required only three in vitro stimulations. Specific CTL T cell bulk cultures stimulated with peptides QAFPQC-
activity was detected at different E:T ratios (Fig. 4B). The
TIL and QAFPQCTILQY killed peptide-loaded RMA-S-
results showed that the 11-mer analogue has a better
B*3501 cells. Only peptide QAFPQCTILQY induced CTL
ability to induce CTL although both peptides are high
that recognized the naturally processed HTLV-1 epitope
binders.
presented by WR-polB-infected P815-B*3501 transfec-
tants. The pol gene expressed in WR-polB encodes aCTL induced in transgenic mice recognize naturally
sequence starting with the residues FPQCTILQY. Peptideprocessed antigen
QAFPQCTIL shares only the FPQCTIL part of WR-polB.
However, CTL induced by peptide QAFPQCTIL cross-To verify the immunogenicity of the 11 peptides, CTL
were investigated for their ability to recognize corre- reacted with FPQCTILQY (Fig. 6) which implies that FPQ-
AID VY 8260 / 6a25$$$$43 11-01-96 14:36:43 viral AP: Virology
109INDUCTION OF HTLV-1 CTL IN HLA-B*3501 TG MICE
FIG. 6. Cross-recognition of peptide epitopes by bulk CTL after three in vitro stimulations. RMA-S and RMA-S-B*3501 cells were pulsed with 1006
M peptide. The effector:target ratio was 40:1.
CTILQY is not an endogenously processed epitope. mainly directed against the tax protein (Jacobson et al.,
Cross-reactivity experiments demonstrated that CTL in- 1990; Parker et al., 1992, 1994; Daenke et al., 1996). Since
duced by peptide QAFPQCTIL lysed RMA-S-B*3501 cells a transgenic mouse model can be exploited for screening
loaded with QAFPQCTILQY, QAFPQCTIL, or FPQCTILQY of potentially immunogenic peptides and vaccination de-
at levels of 30%, whereas CTL induced by QAFPQCTILQY velopment we tested 37 HLA-B*3501 binding peptides
killed targets cells loaded with FPQCTILQY at a two times for their capability to induce CTL. So far, it has been
lower level (15%). These data favor QAFPQCTILQY rather shown that viral peptide-specific, HLA-A2-restricted CTL
than FPQCTILQY as a naturally immunogenic pol HTLV- are effectively induced in transgenic mice expressing a
1 epitope. chimeric HLA-A*0201Kb. Here we report the identification
In order to assess the reactivity of CTL toward the of 11 HLA-B*3501 binding HTLV-1 peptides derived from
four HTLV-1 epitopes (env SPPSTPLLY, VPSPSTPLL, and env, gag, pol, and tax that are immunogenic in HLA-
VPSPSSTPLLY and pol QAFPQCTILQY) we loaded the B*3501 transgenic mice and capable of inducing a CTL
target cells with the corresponding peptides at concen- response. Three peptides derived from pol and env in-
trations of 1005 – 1008 M. The titration curves (Fig. 7) re- duce CTL that recognize naturally processed epitopes
vealed that CTL induced by env peptides are less reac- derived from recombinant vaccinia HTLV-1 proteins.
tive than the pol-induced CTL. The latter recognized It was demonstrated that individual peptides mixed
RMA-S-B*3501 cells loaded with 1008 M peptide, while with P3C-Ser-(Lys)4 induced peptide- and virus-specific
target cells pulsed with 1007 M env-derived peptides HLA-B*3501-restricted CTL in transgenic mice. The CTL
were not killed. mounted a dose-dependent response against peptide-
In summary, 4 of 37 HTLV-1-derived peptides repre- pulsed target cells. RMA-S-B*3501 cells loaded with
sent HTLV-1 epitopes. Although 16 high binders were 1005 –1007 M peptide were lysed, while target cells
tested only 5 induced CTL in HLA-B*3501 transgenic pulsed with lower peptide concentrations were not rec-
mice. The remaining nine peptides may have a high dis- ognized (Fig. 7). The distribution of CTL-inducing pep-
sociation constant which impedes CTL induction as dem- tides among the 16 high, 15 medium, and 6 low binders
onstrated by Kast and co-workers (1996). The low out- was 31%:33%:16% (5:5:1), respectively. Since twice as
come (10.8%) is also attributed to the mismatch of the many high and medium binders as low binders induced
murine and human CD8 binding site. Nevertheless the 4 CTL the peptide’s affinity to HLA-B*3501 seems to play
immunogenic peptides encoded by HTLV-1 env and pol a crucial role in the induction of CTL in HLA-transgenic
are likely candidates for human CTL epitopes. mice (Table 2). In contrast, the affinity of peptides did not
seem to correlate with the cytotoxicity of CTL (Table 3).
DISCUSSION Peptide VPSPSSTPLL is a low-affinity peptide, forming a
less stable peptide–HLA complex, which may explainHLA class I-restricted CTL effectively mediate anti-viral
the low specific lysis (23%) of target cells at a peptideactivity in vivo and in vitro. HTLV-1-specific CTL of carri-
ers or patients with HTLV-1-associated myelopathy are concentration of 1006 M after three stimulations.
FIG. 7. Killing efficiency of bulk CTL after three in vitro stimulations. RMA-S-B*3501 cells were pulsed with 1005 to 1008 M peptide. The effector:target
ratio was 40:1.
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TABLE 2 at position 2 and Tyr, Leu, Ile, or Phe at the C-terminus
(Barber et al., 1995) it is assumed that GAFLTNVPYVPY-CTL Induction Depends on the Peptide–HLAB*3501 Affinity
KRIEEL becomes immunogenic in the context of B7 and
HLA- CTL- B35. The above epitope consists of four potential HLA-
B*3501 No. of inducing B*3501 binding peptides: the high binder GAFLTNVPY
affinity peptides peptides Percentage and low binders VPYKRIEEL(L)(Y). The failure to detect
HLA-B*3501-restricted CTL against endogenously pro-High 16 5 31.3
cessed GAFLTNVPY might result from the lack of flankingMedium 15 5 33.3
Low 6 1 16.7 enzymatic cleavage sites in P815-B*3501 cells.
The other important factor that affects the immunoge-
nicity is the adjuvant. To date most CTL studies using
transgenic mice rely on the application of the peptide asPeptide- as well as virus-specific cytotoxicity has been
emulsion in CFA or in IFA together with a Th epitope.low, ranging from 15 to 40% specific lysis. Considering
CFA is obsolete for future vaccine development becausethe mismatch between the CD8 binding site of the human
of its strong inflammatory side effects (Wiedemann et al.,a3 domain and the murine CD8 molecule, this finding is
1991). Th epitopes are highly efficient in CTL primingnot surprising. It is therefore interesting that the peptide–
when the antigen-presenting cells (APC) express both THLA affinity correlates with the efficacy of peptides to
cell epitopes. However, it is not clear whether in vivo Th-induce CTL in the chimeric transgenic and single
cell-mediated CTL stimulation requires both antigens totransgenic mouse model. Five high binders and five me-
be presented on APC. Since the immunostaining P3C-dium binders induced CTL compared to one low binder
Ser-(Lys)4 emulsified with peptides efficiently induced H-(Table 2). These results are in line with data of endoge-
2Kb-restricted CTL in C57BL mice (Borges et al., 1994) wenously processed CTL epitopes and epitopes identified
adopted a P3C-Ser-(Lys)4-based CTL induction in HLA-in chimeric HLA-A*0201Kb mice (Sette et al., 1994; Went-
B*3501 transgenic mice. In accordance with the study ofworth et al., 1996; van der Burg et al., 1996) which are
Borges and co-workers, priming of CTL without repeatedusually high- or intermediate-affinity peptides with half-
in vitro stimulations was not sufficient to elicit a CTLmaximal binding capacities of 50–500 nM. However, the
response. Peptide–P3C-Ser-(Lys)4 mixtures containingnumber of CTL epitopes identified in a single HLA class
26 nM peptide induced CTL in C57BL mice comparedI transgenic mouse seems to be lower than that in the
to 100 mM peptide required for priming of HLA-B*3501-chimeric HLA class I transgenic mouse. This difference
restricted CTL in transgenic mice. The more than 3800may be explained by the selection of a TCR repertoire
times higher dose is attributed to the fact that not allof high affinity for HLA class I in single HLA class I
antigen-presenting cells express the HLA-B*3501transgenic mouse (Sherman et al., 1992).
transgene. On the other hand the high dose may haveThe immunogenicity of the four HTLV-1 epitopes could
inactivated primary CTL after boosting. Therefore the innot be extrapolated to the human situation because of
vivo priming of CTL by P3C-Ser-(Lys)4 –peptide mixtureslack of data on HLA-B*3501-restricted gag pol and env
needs to be optimized toward a minimum concentration.CTL. However, tax-derived peptide GAFLTNVPY which
The mechanism of CTL induction by P3C-Ser-(Lys)4 hasinduced only peptide-specific CTL was found to be part
not been clarified.of the B7 epitope GAFLTNVPYVPYKRIEEL (Daenke et al.,
The identification of 4 HLA-B*3501-restricted epitopes1996) recognized by the CTL of a HTLV-1 patient. Since
B7 and B35 share common anchor residues Pro or Ala from 37 candidates demonstrated that single HLA
TABLE 3
Efficiency of CTL Induction
HLA-B*3501 Immunization CTL induction
Peptide affinity (No. of mice) (No. of mice) Percentage
QAFPQCTILQY High 8 6 75
QAFPQCTIL High 8 6 75
VPSPSSTPLLY Medium 8 6 75
SPPSTPLLY High 6 4 75
VPSPSSTPLL Low 8 4 50
YPGRVNEIL Medium 6 3 50
GAFLTNVPY Medium 6 3 50
VPSSSSTPL High 8 4 50
YPSLALAPA Medium 6 3 50
YPSLALAPH High 6 3 50
VPSPPSTPLLY Medium 6 2 33
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de The, G. (1985). Antibodies to human T-lymphotropic virus type-Itransgenic mice are still useful for discovering new epi-
in patients with tropical spastic paraparesis. Lancet ii, 407–410.topes by a combination of in vivo priming and in vitro
Gray, G. S., White, M., Bartman, T., and Mann, D. (1990). Envelope gene
stimulation, although chimeric HLA-A*0201Kb (Sette et sequence of HTLV-1 isolate MT-2 and its comparision with other
al., 1993; Ressing et al., 1995) showed a higher efficacy isolates. Virology 177, 391–395.
Hantke, K., and Braun, V. (1973). Covalent binding of lipid to protein:in CTL induction by high and intermediate binders. Since
Diglyceride and amide-linked fatty acid at the N-terminal end of theit is important to demonstrate that the epitopes identified
murein-lipoprotein of the Escherichia coli outer membrane. Eur. J.in the present study are recognized by human T cells,
Biochem. 34, 284–296.
we are currently investigating the induction of CTL de- Hill, A. V. S., Elvin, J., Willis, A. C., Aidoo, M., Allsopp, C. E. M., Gotch,
rived from HTLV-1-infected individuals carrying HLA- F. M., Gao, X. M., Takiguchi, M., Greenwood, B. M., Townsend,
A. R. M., McMichael, A. J., and Whittle, H. C. (1992). Molecular analy-B*3501.
sis of the association of HLA-B53 and resistance to severe malaria.
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